VeraSci
  • Who We Are
    • Leadership
    • Careers
    • Contact Us
  • Therapeutic Expertise
    • Dementia
    • Dermatology
    • Digital Therapeutics
    • Mood Disorders
    • Multiple Sclerosis
    • Parkinson’s Disease
    • Rare & Orphan Disorders
    • Schizophrenia
    • See All
  • What We Do
    • Consulting Services
    • Pathway eCOA
    • Placebo Response Mitigation
    • Endpoints & Assessments
    • Remote Clinical Trials
    • Trial Services
    • Translation & Cultural Adaptation
  • Resources
    • News
    • Events
    • Blog
  • Contact Us
    • Submit an RFP
Select Page

A Multi-Stakeholder Perspective On Assessing Drug Value

by Ashley Davis | Oct 30, 2019 | Publications and Articles

VeraSci’s VP of Regulatory Strategy and Market Access Innovation and former AIFA Director, Dr. Luca Pani, participated in the Boston Consulting Group (BCG) Market Access Roundtable and recently published a paper discussing the variables and challenges involved in the...

Moving the Conversation from Cost to Value: VeraSci Offers New Approach to HEOR and HTA Consulting Led by Dr. Luca Pani

by Ashley Davis | Oct 28, 2019 | Press Releases

VeraSci, a leading provider of innovative scientific and technology services, announces the addition of a new service offering, Value Consulting, a HEOR and HTA consulting service line, addressing the emerging need to demonstrate the pharmacoeconomic value of novel...

Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes

by Ashley Davis | Sep 10, 2019 | Publications and Articles

Abstract Virtual Reality (VR) approaches have had considerable success in measurement of functional capacity. However, it is not clear if factors other than cognitive impairment influence performance on VR measures. Many people with schizophrenia have significant...

VeraSci Receives FDA Grant to Support Qualification of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)

by Ashley Davis | Sep 10, 2019 | Press Releases

VeraSci, a leading provider of innovative scientific and biotechnology services, announced today that they have received an FDA grant to conduct further research on the VRFCAT, their proprietary functional capacity assessment. The VRFCAT has recently been accepted...

VeraSci’s Virtual Reality Functional Capacity Assessment Tool (VRFCAT) Accepted into the FDA’s Clinical Outcome Assessment (COA) Qualification Program

by Ashley Davis | Sep 3, 2019 | Press Releases

VeraSci, a leading provider of innovative scientific and biotechnology services, announced today that their proprietary functional capacity assessment, the VRFCAT has officially been accepted into the FDA’s COA Qualification Program. This FDA program is intended to...
« Older Entries

Recent Posts

  • VeraSci Partners with ActiGraph to Expand the Use of Wearables in Clinical Trials
  • VeraSci Sees Continued Growth Despite COVID-19 Challenges Faced by Clinical Trials Industry
  • Study Supporting Effectiveness of the Placebo-Control Reminder Script (PCRS) Published in Neuropsychopharmacology

Archives

  • VeraSci
  • 3211 Shannon Rd., Suite 300
  • Durham, NC 27707 USA
  • +1.919.401.4642
  • info@verasci.com
  • Who We Are
  • Leadership
  • Careers
  • Contact Us
  • Therapeutic Expertise
  • Dementia & Related Disorders
  • Dermatology
  • Mood Disorders
  • Multiple Sclerosis
  • Parkinson’s Disease & Related Disorders
  • Rare & Orphan Disorders
  • Schizophrenia
  • What We Do
  • Consulting Services
  • Pathway eCOA
  • Endpoints & Assessments
  • Remote Clinical Trials
  • Trial Services
  • Translation & Cultural Adaptation
  • Resources
  • News
  • Events
  • Blog
Privacy Policy Ethics Policy
  • Linkedin
  • Twitter
  • RSS
  • Facebook
ISO 17100 certified ISO 17100 certified ISO 17100 certified
© 2021 Copyright VeraSci. All Rights Reserved.

Our website uses cookies to personalize content, save your preferences, and enhance your overall experience. If you click accept or continue to navigate our website, you agree to having those cookies set on your device. To learn more about adjusting your preferences please visit our Privacy Policy.  Accept  Reject

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non Necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Uncategorized

Undefined cookies are those that are being analyzed and have not been classified into a category as yet.

Advertisement

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Save & Accept